NUMERO: #20220050

Título: WHAT THE MAIN CLINICAL FEATURES OF ONCOLOGICAL PATIENTS WITH MRONJ? A SYSTEMATIC REVIEW AND META-ANALYSIS

Nome do Apresentador: Camila Barcellos CALDERIPE

Categoria do Trabalho: Apresentação Oral de Pôster de Revisões Narrativas ou sistemáticas (PRN)

Área Temática: Estomatologia

Resumo: Objective: To integrate the data published on patients with cancer who underwent antiresorptive drug (ARD) therapy and developed MRONJ into a comprehensive analysis of the clinical features - and to evaluate if some the clinical factors could influence MRONJ staging. Study Design: An electronic search followed by descriptive analyses of the clinic pathological data were performed. Poisson regression was used to evaluate the predictors of the MRONJ stage. Results: In total, 1,598 cases were included. Most cases were reported in women, and the mean age was 66.45±10.5 years. Integumentary system cancer was the main reason for using ARDs, and metastasis occurred in 65.5%(n: 436) patients. The most common etiology of MRONJ was traumatic events. MRONJ stage 2 was the most prevalent. Bisphosphonate monotherapy or combination therapy was used in 77.3% (n: 419) cases, and denosumab was used in 14.4% cases (n: 77). Poisson regression analysis demonstrated that the MRONJ stage was not affected by comorbidities, metastasis, duration of ARD use, or the primary neoplasm site. Conclusion: Nitrogen-containing bisphosphonates (used alone or in combination) are the most common ARDs associated with MRONJ in patients with cancer. Moreover, the primary neoplasm site as well as metastasis have no interference on MRONJ staging.

Autor 1:  Camila Barcellos CALDERIPE

E-mail 1:  [email protected]

Autor 2:   Luíse dos Santos FERREIRA

E-mail 2:  [email protected]

Autor 3 :  Lauren Frenzel SCHUCH

E-mail 3:  [email protected]

Autor 4:  Manoela Domingues MARTINS

E-mail 4:  [email protected]

Autor 5:  Felipe Martins SILVEIRA

E-mail 5:  [email protected]

Autor 6:  Lucas Guimarães ABREU

E-mail 6:  [email protected]

Autor 7:  Ana Carolina Uchoa VASCONCELOS

E-mail 7:  [email protected]